Spero Therapeutics (SPRO)

• Market cap: $52.1M
• 1 day: -4.30%
• 5 days: -13.17%
• 1 month: -20.41%
• 3 months: -28.19%
• 6 months: -28.19%
• Year to date: -37.16%
• 1 year: -29.25%
• 5 years: -91.17%
• 10 years: -91.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Employees: 46

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.91% less ownership

Funds ownership: 25.69% [Q2] → 22.78% (-2.91%) [Q3]

4% less funds holding

Funds holding: 47 [Q2] → 45 (-2) [Q3]

8% less capital invested

Capital invested by funds: $18M [Q2] → $16.5M (-$1.53M) [Q3]

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

69% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 13

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 424% upside
• Avg. target: $5 424% upside
• High target: $5 424% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Evercore ISI Group Josh Schimmer 37% 1-year accuracy 22 / 59 met price target	424% upside $5	In-Line Downgraded	20 Dec 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	424% upside $5	Buy Reiterated	2 Dec 2024